Vericel to Present at Canaccord Genuity Investor Conference

CAMBRIDGE, Mass., Feb. 24, 2016 -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that it will present at the Canaccord Genuity Musculoskeletal Conference in Orlando, FL on Tuesday, March 1, 2016; Vericel CFO Gerard Michel will present a corporate update at 3:30PM EST with a live webcast at http://wsw.com/webcast/canaccord22/vcel. 

About Vericel Corporation
Vericel Corporation is a leader in developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions.  The company markets two autologous cell therapy products in the U.S.: Carticel^® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel^® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area.  Vericel is also developing MACI™, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy.  For more information, please visit the company’s website at www.vcel.com. 

CONTACT:    
Chad Rubin
The Trout Group
[email protected]
(646) 378-2947
or
Lee Stern
The Trout Group
[email protected]
(646) 378-2922